ART Fertility Clinics
Abu Dhabi, Abu Dhabi Emirate, 60202, United Arab Emirates
Location status: Recruiting
NCT Number: NCT06572930
This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.
Interested in participating?
Request Info18 year–39 year
Female
Observational
Abu Dhabi, Abu Dhabi Emirate, 60202, United Arab Emirates
Location status: Recruiting
Ovarian stimulation typically uses transvaginal ultrasound to monitor follicle growth and endometrial condition, with some clinics also tracking serum estradiol and progesterone levels, but often neglecting serum Follicle Stimulation Hormone (FSH). FSH is essential for follicle development, yet its levels can vary widely among women receiving the same dose due to factors like body weight, renal function, and ovarian reserve.
This study aims to identify a minimum effective FSH threshold that ensures optimal follicular growth while avoiding excess administration.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
Time frame: 1 year
serum FSH levels during ovarian stimulation
Contact information is provided by the study sponsor or research team.
Baris Ata, MD
CONTACT
Jonalyn Edades
CONTACT
ART Fertility Clinics LLC
Other
Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders
Acronym: FSH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06839274
OVARIAN STIMULATION
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
View Trial DetailsNCT07515118
Artificial Intelligence, Genital Diseases
Sabadell, Barcelona, Spain
View Trial DetailsNCT06175832
Fertility Preservation, OVARIAN STIMULATION
Ghent, Belgium
View Trial DetailsNCT06732843
OVARIAN STIMULATION, Telomere Length
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
View Trial Details